CytoSorbents to Report Q3 2020 Operating and Financial Results
CytoSorbents Corporation (CTSO) will announce its Q3 2020 financial results on November 4, 2020, after market close. The company specializes in critical care immunotherapy using its CytoSorb® technology for blood purification. Management will host a conference call at 4:45 PM Eastern on the same day to discuss operational and financial progress, which will be followed by a Q&A session. CytoSorb has been used in over 100,000 human treatments and is approved in the EU and 65 countries globally.
- Conference call scheduled for Q3 2020 financial results.
- CytoSorb has been utilized in over 100,000 treatments.
- Access to the technology across 65 countries globally.
- None.
MONMOUTH JUNCTION, N.J., Oct. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2020 financial results after the market close on Wednesday, November 4, 2020. CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2020 followed by a question and answer session.
Conference Call Details:
Date: Wednesday, November 4, 2020
Time: 4:45 PM Eastern
Participant Dial-In: 877-451-6152
Conference ID: 13711756
Live Presentation Webcast: http://public.viavid.com/index.php?id=141897
It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: http://public.viavid.com/index.php?id=141897
An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with in 65 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® has been used in more than 100,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Cytosorbents Contact:
Amy Vogel
732-398-5394
avogel@cytosorbents.com
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors
917-749-1494
jeremy@lifesciadvisors.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-report-q3-2020-operating-and-financial-results-301156615.html
SOURCE CytoSorbents Corporation
FAQ
When will CytoSorbents report Q3 2020 financial results?
What is CytoSorbents' primary product?
What time is the Q3 2020 conference call for CytoSorbents?
In how many countries is CytoSorb approved?
How many human treatments has CytoSorb been used in?
